糖尿病患者糖化血红蛋白控制情况与血液流变学指标相关性分析

目的探讨糖尿病患者糖化血红蛋白(HbA1c)检测数据与血液流变学指标的相关性分析,为其治疗和预防提供参考依据。方法选取2型糖尿病患者142例作为研究对象,根据HbA1c检测结果分成两个不同水平组:A组(69例,控制良好)、B组(73例,控制不佳)。选择同期体检健康者70例作为对照(C组),对3组HbA1c、血液流变学及生化指标检测结果进行对比分析。结果血液流变相关指标除血细胞比容和红细胞变形指数在3组之间差异无统计学意义外(P0.05),其他指标在3组之间差异均有统计学意义(P0.05)。A、C组间比较,血浆黏度、红细胞刚性指数差异无统计学意义(P0.05),余下各指标在不同组之间的差异均有统计学意义(P0.05)。2型糖尿病患者无论HbA1c水平如何,其血液流变指标、三酰甘油及总胆固醇均高于健康人,当患者HbA1c水平控制不佳时,其各指标升高程度更加明显。结论糖尿病患者大多存在血液流变学指标异常,建议临床针对糖尿病患者长期监测HbA1c水平,严格观察血液流变学各项指标的改变,以指导临床治疗达到早期血管保护,以及起到预防糖尿病并发症发生的效果。

Analysis on correlation between glycosylated hemoglobin control situation and hemorheological indicators in diabetes patients

Objective To investigate the correlation between the glycosylated hemoglobin (HbA1c) detection data and hemo‐rheological indicators in diabetes patients to provide reference basis for its treatment and prevention .Methods One hundred and forty‐two patients with typeⅡdiabetes mellitus(T2DM ) in the hospital were selected as the research subjects and divided into the A group(69 cases ,better control) and B group(73 cases ,poor control) according to the HbA1c detection results .Contemporaneous 70 healthy individuals undergoing physical examination were selected as the control (C group) .The detection results of HbA1c ,hemo‐rheology and biochemical indexes were performed the contrastive analysis .Results Except hematocrit and erythrocyte deformation index without statistical difference among 3 groups(P>0 .05) ,the other hemorheologic indicators had statistical differences among 3 groups(P<0 .05) .No matter the HbA1c level in T2DM patients ,the hemorheological indexes ,triglyceride and total cholesterol were higher than those in the healthy people ,When the HbA1c leve was poorly controlled ,the increase degresss of various indexes were more significant .Conclusion The abnormality of hemorheology indices exist in most of the patients with diabetes mellitus .It is recommended that clinic should monitor the HbA1c level for long term and strictly observe the change of hemorheology indexes to guide the clinical treatment for reaching the effects of early vascular protection and prevention of diabetic complications .